Focus: Swedish Orphan Biovitrum (Sobi) is a specialty biopharmaceutical company headquartered in Waltham, MA, focused on rare diseases, oncology, and immunology through biologic therapeutics. The company operates as a publicly traded entity with a portfolio heavily concentrated in established biologics.
Profile data last refreshed 12h ago · AI intelligence enriched 1mo ago
Stable — net +3 jobs in 30d
49 added, 46 removed. Backfill posture.
Sobi offers stability for those seeking established product experience in rare diseases and immunology, but career trajectory depends heavily on pipeline advancement and mitigation of severe revenue concentration risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core revenue driver (99% of revenue) but facing imminent loss of exclusivity, making it the critical inflection point for company viability.
Help build intelligence for Swedish Orphan Biovitrum
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Swedish Orphan Biovitrum's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Minor revenue contributor approaching exclusivity loss with minimal market penetration.
Marginal revenue product nearing end-of-life with limited clinical relevance.
Extended exclusivity period to 2033 provides longer runway than other legacy products, representing strategic anchor for rare disease franchise.
Early-stage oncology supporting product facing exclusivity loss without clear value repositioning.
Slate Medicines Strengthens Board of Directors with Appointment of Mark W. Hahn - The Manila Times
Slate Medicines Strengthens Board of Directors with Appointment of Mark W. Hahn The Manila Times
FDA Temporarily Suspending Public Release of New Drug Rejection Letters - The Well News
FDA Temporarily Suspending Public Release of New Drug Rejection Letters The Well News
FDA returns to releasing pharma rejection letters with 14 new CRLs - Endpoints News
FDA returns to releasing pharma rejection letters with 14 new CRLs Endpoints News
Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN - GlobeNewswire
Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN GlobeNewswire
Gout Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
Gout Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight Barchart.com
Gout Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
Gout Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight Barchart.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Promoting clinical trials in pediatric IgA nephropathy through extrapolation: an artificial intelligence-enhanced literature review of the disease in pediatrics sponsored by the Kidney Health Initiative.
Age at onset and cumulative initial prednisolone dose predict frequent relapses in steroid-sensitive nephrotic syndrome: an individual participant data systematic review and meta-analysis of placebo-controlled RCTs.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo